IVF vs MARA

For growth investors, INVO Fertility, Inc.

(IVF) is the stronger pick with 116. 3% revenue growth year-over-year, versus 38. 2% for Marathon Digital Holdings, Inc. (MARA). Analysts rate Marathon Digital Holdings, Inc. (MARA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Marathon Digital Holdings, Inc.

(MARA) delivered a total return of -53. 5%, compared to -100. 0% for INVO Fertility, Inc. (IVF). Over 10 years, the gap is even starker: MARA returned -50. 7% versus IVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), INVO Fertility, Inc.

(IVF) is the lower-risk stock at 1. 29β versus Marathon Digital Holdings, Inc. 's 3. 10β — meaning MARA is approximately 141% more volatile than IVF relative to the S&P 500. On balance sheet safety, INVO Fertility, Inc. (IVF) carries a lower debt/equity ratio of 78% versus 105% for Marathon Digital Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INVO Fertility, Inc.

(IVF) is pulling ahead at 116. 3% versus 38. 2% for Marathon Digital Holdings, Inc. (MARA). On earnings-per-share growth, the picture is similar: INVO Fertility, Inc. grew EPS 55. 2% year-over-year, compared to -314. 5% for Marathon Digital Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

INVO Fertility, Inc.

(IVF) is the more profitable company, earning -139. 3% net margin versus -144. 6% for Marathon Digital Holdings, Inc. — meaning it keeps -139. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MARA leads at -90. 6% versus -124. 4% for IVF. At the gross margin level — before operating expenses — IVF leads at 44. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, INVO Fertility, Inc.

(IVF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29)). Marathon Digital Holdings, Inc. (MARA) carries a higher beta of 3. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IVF: -100. 0%, MARA: -50. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IVF (Healthcare) and MARA (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.